系统性rho激酶抑制剂白莫硫地尔治疗眼部移植物抗宿主病。

IF 3.5 2区医学 Q1 OPHTHALMOLOGY

British Journal of Ophthalmology Pub Date : 2025-10-20 DOI:10.1136/bjo-2025-327877

Charlyn Gomez,Fernando Martinez Guasch,Vishal Jhanji,Sarah Brem Sunshine

{"title":"系统性rho激酶抑制剂白莫硫地尔治疗眼部移植物抗宿主病。","authors":"Charlyn Gomez,Fernando Martinez Guasch,Vishal Jhanji,Sarah Brem Sunshine","doi":"10.1136/bjo-2025-327877","DOIUrl":null,"url":null,"abstract":"We aimed to describe the response of chronic ocular graft versus host disease (oGVHD) to systemic belumosudil. A total of seven patients were included. Five patients underwent allogeneic stem cell transplant and two patients received allogeneic peripheral blood stem cell transplant. After starting belumodusil treatment (average treatment duration 22.3 months), three patients had reduced corneal fluorescein staining. Resolution of filamentary keratopathy was noted in four patients. Ocular discomfort score improved in four patients. Visual acuity remained stable for all patients. Our case series showed that belumosudil use in oGvHD may offer improvement or stabilisation and should be investigated further.","PeriodicalId":9313,"journal":{"name":"British Journal of Ophthalmology","volume":"29 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease.\",\"authors\":\"Charlyn Gomez,Fernando Martinez Guasch,Vishal Jhanji,Sarah Brem Sunshine\",\"doi\":\"10.1136/bjo-2025-327877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We aimed to describe the response of chronic ocular graft versus host disease (oGVHD) to systemic belumosudil. A total of seven patients were included. Five patients underwent allogeneic stem cell transplant and two patients received allogeneic peripheral blood stem cell transplant. After starting belumodusil treatment (average treatment duration 22.3 months), three patients had reduced corneal fluorescein staining. Resolution of filamentary keratopathy was noted in four patients. Ocular discomfort score improved in four patients. Visual acuity remained stable for all patients. Our case series showed that belumosudil use in oGvHD may offer improvement or stabilisation and should be investigated further.\",\"PeriodicalId\":9313,\"journal\":{\"name\":\"British Journal of Ophthalmology\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bjo-2025-327877\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bjo-2025-327877","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们的目的是描述慢性眼移植物抗宿主病（oGVHD）对全身白莫硫地尔的反应。共纳入7例患者。5例患者行同种异体干细胞移植，2例患者行同种异体外周血干细胞移植。在开始贝莫多西治疗后（平均治疗时间22.3个月），3例患者角膜荧光素染色降低。4例患者丝状角膜病变消退。4例患者眼部不适评分改善。所有患者的视力均保持稳定。我们的病例系列表明，在oGvHD中使用白莫硫地尔可能会改善或稳定，应该进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease.

We aimed to describe the response of chronic ocular graft versus host disease (oGVHD) to systemic belumosudil. A total of seven patients were included. Five patients underwent allogeneic stem cell transplant and two patients received allogeneic peripheral blood stem cell transplant. After starting belumodusil treatment (average treatment duration 22.3 months), three patients had reduced corneal fluorescein staining. Resolution of filamentary keratopathy was noted in four patients. Ocular discomfort score improved in four patients. Visual acuity remained stable for all patients. Our case series showed that belumosudil use in oGvHD may offer improvement or stabilisation and should be investigated further.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British Journal of Ophthalmology 医学-眼科学

CiteScore

10.30

自引率

2.40%

发文量

213

审稿时长

3-6 weeks

期刊介绍： The British Journal of Ophthalmology (BJO) is an international peer-reviewed journal for ophthalmologists and visual science specialists. BJO publishes clinical investigations, clinical observations, and clinically relevant laboratory investigations related to ophthalmology. It also provides major reviews and also publishes manuscripts covering regional issues in a global context.